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WS15.1 Volume increase in alveolar type II cells following fusion
dependent activation of P2X4 receptors on lamellar bodies −
linking secretion and ﬂuid transport in the lung?
K. Thompson1, E. Hecht2, O. Wittekindt1, P. Miklavc1, C. Kranz2, P. Dietl1,
M. Frick1. 1Institute of General Physiology, University of Ulm, Ulm, Germany;
2Institute of Analytical and Bioanalytical Chemistry, University of Ulm, Ulm,
Germany
Maintenance of a healthy lung environment relies on proper ﬂuid transport within
the lungs. While it has been thought that the alveolar epithelium may play a
part in regulating ﬂuid homeostasis, this has remained largely undetermined. The
alveolar epithelium consists of the alveolar type I and II (ATII) cells. ATII cells are
responsible for secretion of lung surfactant through exocytosis of lamellar bodies
(LBs). Recently we have described that exocytic fusion of LBs with the plasma
membrane results in a non-selective, transient, and inward-rectifying, cation current.
This inward-cation current occurs across the purinergic receptor, P2X4, which
is located on the membranes of fused LBs (PNAS 2011, 108(35):14503−8). It
is possible that directed ion transport across the ATII cell results in either ﬂuid
secretion or absorption into or from the pulmonary hypophase. This leads to the
possibility that ﬂuid transport across the alveolar epithelium is modulated by this
fusion-activated cation inﬂux following LB exocytosis. Atomic force microscopy
(AFM) and ﬂuorescence experiments conﬁrmed that exocytosis of LBs following
ATP stimulation results in an instant increase in ATII cell volume, and is then
regulated within minutes. In ATII cells with LBS fusing with the plasma membrane
following ATP stimulation, there was a 30% increase in cell height following fusion.
This effect was not seen however in ATII cells without fusion of the LBs with the
plasma membrane. These data indicate a coupling of surfactant secretion (via LB
fusion) and the regulation of ﬂuid transport in the lung.
WS15.2 Airway surface liquid layer height in cystic ﬁbrosis bronchial
epithelial cells is increased by lipoxin A4 via an apical
ATP release activating a P2Y receptor pathway
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Cystic ﬁbrosis (CF) is caused by a mutation of the Cystic Fibrosis Transmembrane
conductance Regulator (CFTR) gene. One of the resulting abnormalities is dehydra-
tion of the Airway Surface Liquid (ASL) by a dysfunctional ion transport, leading
to impaired mucocillary clearance, lung infection and inﬂammation. The eicosanoid
LXA4 is a signal of the resolution of inﬂammation, and is decreased in the lungs
of patients with CF (Karp et al, 2004). The decrease in LXA4 could participate
to chronic airway inﬂammation in CF. Using live cell imaging, we investigated
the role of LXA4 on ASL height in Human Bronchial Epithelial Cells (HBE) and
Human Cystic Fibrosis Bronchial Epithelial (HCFBE) cells cultured in air/liquid
interface. LXA4 and its stable analogue TA39 increase ASL height in a dose and
time dependent manner in both the HBE and HCFBE cells. LXA4 causes apical
ATP release from HBE and HCFBE cells which was inhibited by a Panx1 inhibitor,
carbenoxolone. Inhibition of the P2Y11 receptors with reactive blue 2 and NF340,
prevents the ASL height increase induced by LXA4. The ASL height increase and
ATP release induced by LXA4 were both blocked by the FPR2 receptor inhibitor,
Boc-2. Our results indicate a novel role for LXA4 in restoring ASL height in
CF airways via a mechanism involving the FPR2 receptor, apical ATP release
and P2Y11 receptor activation. This could lead to a new therapeutic route for
CF patients.
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WS15.3 Channel activating proteases (CAPS): identiﬁcation of novel
targets for correcting sodium channel dysfunction in cystic
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Proteolytic cleavage of the endogenous a and g subunits of ENaC [by channel
activating proteases (CAPS)], is a key regulatory mechanism for ENaC channel
activity. Excessive ENaC activity is a feature of CF which contributes to the deple-
tion of the ASL (airway surface liquid) with resultant impairment of mucociliary
function. Growing evidence suggests protease/protease inhibitor imbalance may
underlie increased Na+ absorption in CF airway epithelia therefore inhibition of
the CAPS-ENaC signalling axis represents a potential therapeutic target to restore
mucociliary function.
Our group has developed a panel of active-site directed afﬁnity probes which
target and inhibit trypsin-like proteases (potential CAPS) including the broad-
spectrum inhibitor QUB-TL1. QUB-TLI selectively inhibits recombinant trypsin-
like proteases (trypsin, prostasin, furin) without affecting non-trypsin like proteases
(neutrophil elastase); and furthermore inhibits trypsin-like protease activity in cell-
conditioned media (CCM) retained from epithelial cell cultures. By targeting the
biotin reporter group on QUB-TL1 with anti-streptavidin-HRP we can visualise
several candidate CAPS in
1. intact non-CF and CF epithelial cells (HBE/CFBE cell lines and primary nasal
epithelial cells); and
2. CCM from these epithelial cell cultures.
Conclusion: Our broad-spectrum afﬁnity based probe detects several trypsin-like
species in non-CF and CF epithelial cell preparations. This paves the way for
further characterisation of these proteases and an assessment of their effect on
ENaC function.
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Defective CFTR function in the airway epithelium is responsible for CF patient lung
disease. CFTR represents the most important pathway for chloride (Cl−) secretion
in human bronchial epithelial cells. Calcium activated Cl− channels (CaCC) are
also an important pathway of Cl− secretion. In 2008, three teams identiﬁed ANO1
(Anoctamine 1) as a CaCC candidate. The main aim of this study is to characterize
ANO1 protein in CF vs non CF context. This aim is divided into three distinct
parts that are intended to:
– Compare ANO1 expression, localization and activity in CF vs non CF context
– Understand mechanisms regulating ANO1 activity
– Determine whether there are differences between CF and non CF alternative
splicing
Our results show that ANO1 expression and activity are signiﬁcantly decreased
in CF models (cell lines, mice and lung explants). ANO1 is expressed at plasma
membrane in CF and non CF cells. Preliminary results shows that ANO1 activity
is reduced in presence of Mek1,2 inhibitors. Alternative splicing study shows that
expression of some exons seems to be different between CF and non CF models.
We conclude that decreased ANO1 activity in CF cells could be explained by de-
creased ANO1 mRNA and protein expression and may contribute to the worsening
of ionic imbalance. Moreover, ANO1 seems to be regulated by Erk1,2 pathways
although these results should be conﬁrmed. First results obtained on alternative
splicing seem to show that CF or non CF context induces different alternative
splicing that could affect ANO1 function. All of these results lead us to think that
this Cl− channel could be a potential pharmacological target for the treatment of
CF patients.
